Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 12, 2007. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share plan transactions. The following transaction prices are noted:
- Ordinary Shares: GBP 13.92 per share
- Ordinary Share ADRs: $52.98 per ADR
Material Changes
The filing details an increase in notional interests in Ordinary Shares and ADRs for various executives following the notional re-investment of the dividend paid to shareholders on January 4, 2007. No comparative financial data or material changes to the company's financial position are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It notes that notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three-year measurement period. The notification complies with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Important Facts for Investors
- This filing is a regulatory disclosure of insider share plan activity, not a financial results report.
- Transactions occurred on January 12, 2007, involving the re-investment of dividends paid on January 4, 2007.
- Specific share counts were updated for 15 named individuals, including Dr. JP Garnier and Mr. A P Witty.
- Financial performance metrics for the period are not included in this document.